0,grounded theory
1,superfamily
2,angiogenesis
3,cardiac resynchronization
4,doxorubicin
5,ven
6,quality
7,risk factors
8,btt
9,calls
10,adenoviral vector
11,prospective
12,t1-mapping sequence
13,trichrome
14,skeletal
15,northwest
16,aerobic
17,bound
18,acute kidney
19,processing
20,compliance
21,analyze
22,2+)-uptake
23,(-)-erc
24,decongestion
25,strength
26,diet
27,thromboembolism
28,apex
29,panel
30,hdl-induced
31,moderate-intensity
32,device-related
33,inability
34,st-segment-elevation
35,case-control
36,blunts
37,anticoagulants
38,benefits
39,raloxifene
40,acp
41,post-lvad
42,body
43,biosynthetic
44,ventricular-pulmonary
45,reversible
46,chloride
47,dilation
48,evidence-based
49,beneficial
50,seventy-seven
51,etiologic
52,atp
53,randomised
54,clustering
55,sd
56,blocker
57,skinfold thickness
58,echo-doppler
59,ans
60,chain
61,controls
62,sodium-restricted
63,hearts
64,patterning
65,process
66,whites
67,centre
68,degenerative
69,edge-to-edge
70,flow
71,morphological
72,raloxifene-treated
73,main
74,25mg
75,degs
76,immunodetection
77,alternatives
78,flow-mediated dilatation diameter
79,anti-neoplastic
80,computed
81,myocardial infarction
82,exogenous variants
83,sensitivity
84,wall
85,all-cause hospitalization
86,cascade
87,np
88,channel
89,non-ischemic
90,myocarditis
91,open-label
92,morpholino-based
93,ami
94,risk-standardized mortality
95,health-related
96,protocol
97,noncardiac
98,tapse
99,adjusted
100,accounting
101,transcript
102,pacemakers
103,aric
104,thrombotic
105,mr-proadm
106,hno
107,diuretics
108,pathways
109,transseptal
110,ecs
111,untreated
112,histologic
113,histologically
114,differentially
115,revision
116,acetyl-lysine
117,safety
118,study-drug
119,etidronate
120,nurses
121,growth
122,mechanistic
123,atrial
124,cinahl
125,end-of-life
126,ventricular ejection
127,breathing
128,adjustment
129,allogeneic
130,measures
131,antihyperglycemic
132,cost
133,upstream
134,lability
135,modulates
136,screening
137,active
138,binding
139,diagnostic
140,intolerance
141,multihospital
142,btes
143,short-term
144,antitumor
145,differential
146,transitions of care
147,dpp-4
148,differential response
149,primary care
150,ratio
151,exerts
152,radiation
153,correlations
154,rm
155,heart failure-related
156,strategies
157,exploratory factor
158,cxl-1020
159,tnf)α
160,recruitment
161,overlapped
162,surgery
163,adherence
164,donor
165,oxygen
166,reasons
167,walk distance
168,multimarker-based
169,abolished
170,conclusion
171,economic
172,ventricle
173,peak
174,pressure gradient
175,sitagliptin
176,consequences
177,icds
178,proteins
179,hypertensive
180,defects
181,data
182,joint effect
183,attributable
184,time-dependent covariates
185,load-corrected
186,cpcs
187,internal
188,coupling
189,partial reversal
190,avp
191,cardiomyopathic
192,age-by-lvef
193,ages
194,synchrony
195,coronary artery
196,hepatic
197,readmission
198,barriers
199,bolus
200,triangular resection
201,high-cost
202,lean
203,pah
204,cardiovascular
205,signs of heart failure
206,hnorm
207,mechanism
208,long-term effects
209,throughput
210,extubated
211,heart
212,ffm
213,action
214,mis
215,single-center
216,ref
217,paradigm shift
218,hand-searching
219,post-acute
220,signed-rank
221,rna
222,er
223,ml
224,postoperative
225,t2d
226,osprey
227,va-rt cohorts
228,divided
229,srd
230,mixed
231,re-activating
232,strengths
233,meta-analysis
234,compensated
235,walking
236,i-iii
237,compensatory
238,mechanical
239,virtual cohorts
240,cells
241,dynamic
242,mitochondrial
243,therapeutic
244,conclusions—low-volume
245,anti-inflammatory
246,phosphocreatine
247,leaders
248,drug-free
249,pure epicatechin
250,infarct
251,endothelial-protective
252,cpgs
253,ros
254,sci
255,co2
256,proof-of-principle
257,full-length scn5a
258,implantable
259,hemodynamic
260,poc
261,anaesthesia
262,mediated
263,dt
264,deacetylases
265,autonomic
266,myocardial
267,inflammation
268,concurrent
269,electromechanical
270,pressure-volume
271,mortality
272,center
273,reversal
274,double-blind
275,documentation
276,tonometric
277,deciles
278,vasculature
279,cardiomyocyte
280,aac
281,phenylephrine
282,isolated
283,infancy
284,mediator
285,non-urbanized
286,safe
287,transcription
288,amyloidosis
289,copd
290,anecdotal
291,tension
292,ckd
293,ecct
294,nonmitochondrial
295,inflammatory
296,paced
297,pvf
298,allocation
299,unclear
300,swine
301,feeding
302,vehicle
303,ambulatory
304,muscle-wasting
305,foundation
306,equitable
307,right ventricle
308,transplantation
309,relative value
310,mdc95
311,cd34+vegfr2
312,doctors
313,sparing
314,overweight
315,rgk
316,vascular
317,aim
318,defibrillator-only
319,subpulmonary
320,mass
321,non-randomized
322,epidemiology
323,discharge
324,survivors
325,congestive
326,cardiologist
327,long-term mortality
328,right
329,energy
330,acs
331,recognition
332,block
333,hyperacetylation
334,epigenetic
335,classification of diseases
336,nonprescribing
337,ethnicity
338,predictors
339,perturbed
340,duplicate
341,phosphorylation
342,restoration
343,breakdown
344,transfusion
345,regimen
346,xo-mediated
347,dd
348,apoptosis
349,cancer
350,chemotherapy
351,left-to-right
352,advocate
353,bmi-matched
354,exchange
355,high-dose
356,subdomains
357,at-risk
358,insulin-resistance
359,dramatic induction
360,duration
361,angina
362,myocardium
363,doxorubicin-induced
364,treadmill
365,aldosterone
366,phenylephrine-mediated
367,single-arm
368,carbohydrates
369,centrifugal-flow
370,bioinformatic
371,oht
372,studies
373,viable
374,tone
375,clcnka
376,myocardial perfusion
377,outcome
378,lvad
379,echocardiography
380,reviewers
381,upr
382,stressors
383,continuous-flow
384,cardiologists
385,sham-inv
386,nondiabetes
387,gadolinium-chelate
388,range
389,removal
390,sacubiltril
391,coral
392,auc
393,causes of death
394,myosin
395,mdc
396,monoclonal
397,placebo-controlled
398,failure
399,recommendations
400,natremia
401,yield
402,forty-six
403,renin-angiotensin-aldosterone
404,assembly
405,erk1
406,random-effects
407,cyclase
408,explanted
409,renastur
410,magnetic
411,branches
412,end-systole
413,non-diastolic
414,g-protein
415,conscious rabbits
416,nonfailing
417,event-free rate
418,channel-dependent
419,harms
420,basal rotations
421,pathophysiological
422,resting
423,ch
424,qt
425,biomarker-guided
426,real-world
427,adhesion
428,circulatory
429,adverse
430,nondiabetic
431,downregulation
432,camp-dependent
433,noninvasive
434,slope
435,axis
436,emergency
437,n2bus
438,growth factor
439,transforming
440,sphingosine-1-phosphate
441,uptitrations
442,exclusive
443,chromatin
444,transplant
445,mva
446,diuretic
447,univariate
448,turbulence
449,noncardiologist
450,insurance
451,lusitropic
452,descriptive
453,ste
454,growth factor-β
455,thickness
456,mrna
457,rhythm
458,cardioverter
459,psss
460,production
461,groups
462,induction
463,s'septal
464,hr
465,atropine infusion
466,uncovered
467,leu3-gly4
468,statistically
469,resynchronization-defibrillation
470,hospital-to-home
471,atheromatous
472,technology
473,lcx
474,modality
475,outweigh
476,attributed
477,heart rate
478,paediatric
479,anthracycline-related
480,early-onset
481,β-blocker
482,induce
483,nps
484,practices
485,lp-pla2
486,physicians
487,tolerated
488,renal
489,muscle
490,dearth
491,orientation
492,benefit
493,inpatient
494,adoption
495,myocardial infarction-both
496,heart failure
497,pacing
498,physician
499,effect
500,life-sustaining
501,free wall
502,health care
503,congenital lesions
504,nursing
505,chelation
506,particles
507,coronary
508,blood pressure
509,knockdown
510,fatigue
511,correlation coefficient
512,transiently
513,electrocardiographers
514,hfvt(+)
515,hrv
516,reoperation
517,borderline
518,(-)-epicatechin-rich
519,inventory
520,hospitalization
521,technique
522,care
523,implants
524,combination
525,multiacquisition
526,all-cause
527,ecgs
528,beat-to-beat
529,cardioprotection
530,asymptomatic
531,clin
532,protection
533,advanced
534,adenosine
535,key
536,icd
537,cdp
538,high-strength
539,loss
540,tricuspid
541,coprimary
542,t2
543,pulmonary
544,epinephrine
545,ring
546,gluconeogenesis
547,obese
548,proangiogenic
549,abnormal
550,unilateral
551,diuretic effect
552,utility
553,differentiation
554,va
555,research
556,repair
557,economic considerations
558,hospitalizations
559,myxomas
560,ecmo+vad
561,non-frail
562,family
563,lvet
564,lvas
565,renin-angiotensin
566,outpatients
567,pressures
568,outcome-monitoring
569,exacerbates
570,nurse
571,shuttle
572,twist
573,o2
574,ms
575,twenty-seven
576,abnormalities
577,extracorporeal
578,summary
579,cardiology
580,risk of mortality
581,agents
582,phospholamban
583,uninephrectomy
584,reproducible
585,thromboembolic
586,performance
587,immunoprecipitation
588,embolism
589,single -
590,transcatheter
591,aortic valve
592,conductance
593,tissuefaxs
594,x-ray
595,embryonic
596,cross-linking
597,medication
598,microarray
599,assays
600,briefing
601,concentrations
602,guideline
603,all-cause hospitalizations
604,hfpef
605,acc
606,trial-cardiac
607,telephone
608,pathological
609,low-risk
610,nontraumatic
611,cation
612,single-institution
613,mechanisms
614,dilatation
615,resolved
616,procedure
617,angiotensin-receptor
618,repression
619,arterial
620,three
621,methods
622,power spectral
623,shunts
624,lvh
625,translocation
626,transcriptional
627,pre-pd
628,risks
629,scales
630,rat
631,dynamics
632,transmitral
633,abstract
634,defibrillator
635,nbdmard
636,neurotransmission
637,wasting
638,risk
639,multivariate regression
640,regulator
641,separate
642,uptake
643,guideline-recommended
644,protective
645,microscopy
646,t-score
647,pharmacologic
648,importance
649,defibrillators
650,left ventricle
651,iv
652,cytochrome
653,chemotherapy-induced
654,circulatory arrest
655,furthermore
656,dissemination
657,emission
658,subproteome
659,tachyarrhythmias
660,collagen
661,signaling
662,programmes
663,natriuretic peptide
664,anemia
665,dialysis
666,measured
667,networks
668,plasma
669,stress
670,maladaptive
671,first-in-man
672,measurement
673,penalties
674,bottleneck
675,biventricular
676,cardiorespiratory
677,multivariable
678,therapeutics
679,thigh
680,snp
681,ahf
682,components
683,debilitating
684,pharmaceutically
685,ras
686,validity
687,rehospitalization
688,ventricular fibrillation
689,tethering
690,transformed
691,postmenopausal
692,translating
693,intubated
694,ejection
695,periprocedural
696,point of death
697,cpg
698,woman
699,genes
700,metabolism
701,residual
702,atrium
703,vehicle-treated
704,senescence
705,functional electrical stimulation
706,hfpsi
707,valve
708,savings
709,actin
710,absorptiometry
711,postmarketing
712,bisphosphonates
713,water
714,budget
715,packages
716,metric
717,nitroxyl
718,facilities
719,codes
720,end-systolic pressure
721,explant
722,emd
723,single-cohort
724,stiffness
725,interventions
726,inotropes
727,sample
728,bets
729,systolic
730,placebo
731,tac-induced
732,east
733,eov
734,ratings
735,irs1
736,discrepancy
737,driveline
738,protocol-driven
739,beta-blockers
740,bodies
741,wedge
742,flow velocities
743,mirnas
744,subunits
745,peripheral
746,flow-mediated dilatation
747,agonist
748,psoriasis
749,hypertrophy
750,mlhf
751,ies
752,antitachycardia
753,performance measurement
754,damage
755,blacks
756,wt
757,late-activated
758,caring
759,logistic
760,acetyltransferase
761,aortic
762,spite
763,circulation
764,within-day test-retest
765,inducible
766,wave
767,outpatient
768,statistical
769,higher-than-expected
770,antihypertensive
771,crf
772,colony-forming
773,recent
774,power
775,objective
776,office
777,outflow
778,efficiency
779,pde2
780,etiology
781,diastolic
782,phenylephrine-induced
783,development
784,net-reclassification-improvement
785,decompensated
786,biomedical
787,low-volume
788,lvads
789,non-linear measures
790,pathobiology
791,survival
792,triggers
793,sdrr
794,clinical
795,opening
796,murmurs
797,mi-induced
798,bb
799,procedure-related
800,relations
801,feasibility
802,endopeptidase
803,weight loss
804,life
805,administrative
806,tnf
807,undecided
808,office-based
809,vt
810,drug
811,systematic
812,outcomes
813,remote
814,better-than-usual
815,rate of death
816,states
817,refractory
818,exertional
819,stenotic
820,crt-d
821,physical therapy
822,velocity
823,trial
824,tertiary
825,pressure-overload-induced
826,mutually
827,hyperinsulinemia
828,device
829,morbidity
830,health
831,breathlessness
832,risk-adjusted
833,blockers
834,width
835,pioglitazone
836,resistin
837,selection
838,revascularization
839,neprilysin
840,interactors
841,autopsy
842,recovery
843,severity of heart failure
844,intubation
845,co-morbidities
846,propensity-score
847,exposure
848,two-center
849,switched
850,ratios
851,sodium
852,confounders
853,barrier
854,overlapping
855,published
856,antibodies
857,robot-assisted
858,resources
859,non-aas
860,severe-end-stage
861,adult
862,hfvt(-)
863,left-hand
864,mistargeting
865,bmi
866,tolvaptan
867,signaling pathway
868,electron
869,erythropoiesis-stimulating
870,functions
871,cascades
872,m2
873,tools
874,reactivation
875,nodularity
876,s1pr1s
877,prescribing
878,disease
879,antiarrhythmic
880,metrics
881,pay-for-performance
882,low-sodium
883,complex
884,mi
885,induced recovery
886,isoelectric
887,emean
888,insufficiency
889,hemolysis
890,mice
891,statistics
892,β-blockade
893,time-domain
894,post-aac
895,samples
896,hdl
897,ablation
898,mpsms
899,assessing
900,driven
901,study
902,naturally
903,peptides
904,functional
905,sport
906,spectral
907,contractile
908,blood
909,noc
910,shortening
911,insertion
912,confidence interval
913,infarction
914,micronutrients
915,contextual factors
916,hypertension
917,trials
918,nri
919,black
920,pf
921,follow-up
922,inactive
923,non-dnx
924,hospitalized
925,cardiac-resynchronization
926,intestinal
927,oxygenation
928,retrospective
929,analysis
930,deposition
931,exacerbation
932,angiotensin-aldosterone pathway
933,bet
934,telehealth
935,hypoxia
936,bridge to transplantation
937,unstable
938,quality of life
939,retention
940,cardiomyocytes
941,reclassification
942,tachypacing-induced
943,mitogen-activated
944,factors
945,burden
946,vena
947,normalization
948,toxicity
949,psychometric
950,rates
951,high-frequency
952,hyperlipidaemia
953,cardioverter-defibrillators
954,objectives
955,acetyltransferases
956,elicited
957,conservation
958,first-ever
959,sequence-specific
960,testosterone
961,training
962,extracted
963,end-systolic
964,obstruction
965,walking distance
966,myocytes
967,schfi
968,systems
969,dithiothreitol
970,experimental
971,resolution
972,study-related
973,subvalvular
974,ventricles
975,obesity
976,exercise
977,nonpublic
978,myocyte
979,inotropic
980,elucidate mechanisms
981,conditioning
982,ischemia
983,non-biological
984,blocks
985,haplotype
986,oxidative
987,wave ratio
988,methylatropine
989,diagnosis
990,administration
991,ethics
992,biology
993,nitric oxide
994,ivabradine-treated
995,dialysis-dependent
996,pb
997,criteria
998,extract
999,nonstandardized
1000,incident
1001,enrichment
1002,low-quality
1003,fixed-rate
1004,referral
1005,pef
1006,atypical
1007,first-in-class angiotensin
1008,telemonitoring
1009,transthoracic echocardiography
1010,trials-enriching
1011,tug
1012,across-the-board
1013,e'lateral
1014,hemodynamics
1015,competitive
1016,aged
1017,offset
1018,chemical
1019,breast
1020,eligibility
1021,procedures
1022,cms
1023,ppr
1024,pressure-overload
1025,sts
1026,nonselective
1027,aor
1028,high-risk
1029,mass index
1030,caloric
1031,injury
1032,randomised-controlled
1033,factorial
1034,pollution
1035,index
1036,cognitive
1037,bcl-2
1038,β-ar
1039,materials
1040,eo-cfus
1041,pad
1042,inotrope-dependent
1043,reporting
1044,fluctuations
1045,life-threatening
1046,intermediate
1047,acetylcholinesterase
1048,fluid
1049,ventricular
1050,strategy
1051,frequency
1052,homeostasis
1053,pre-participation
1054,models
1055,substitution
1056,multiple-procedure
1057,food-frequency
1058,activators
1059,long-term survival
1060,setting
1061,rvpo
1062,catheterization
1063,nonsurvivors
1064,hhf
1065,refill
1066,cyclic
1067,tomographic angiography
1068,risk of stroke
1069,downstream
1070,in-trial
1071,rnas
1072,neonatal rat
1073,dysfunction
1074,electromechanical delay
1075,monophosphate
1076,multiorgan
1077,rabbits
1078,dobutamine
1079,camp
1080,murmur
1081,maintenance
1082,bleeding
1083,mass ratio
1084,angiotensin-converting
1085,mri
1086,immunoreactive
1087,pyridostigmine
1088,sex
1089,biomarkers
1090,protein
1091,control
1092,insulin
1093,interagency
1094,cytoskeletal
1095,et
1096,haemodynamic
1097,background
1098,natural
1099,echocardiograms
1100,motions
1101,subgroups
1102,patient-level
1103,magnetically
1104,assessment
1105,cost-effectiveness ratios
1106,generator
1107,pulseless
1108,tachy -
1109,washout
1110,measuring
1111,driving
1112,stimulation
1113,relationships
1114,long-term ventricular
1115,transduction
1116,abrogate
1117,support
1118,unsuitable
1119,recurrent
1120,svr
1121,post-transplant
1122,acr
1123,invasive
1124,tachycardia
1125,liver-specific
1126,laboratory
1127,line
1128,coagulability
1129,non-sudden
1130,publications
1131,home
1132,first-in-class
1133,medical
1134,distance
1135,cohort
1136,assist
1137,climate
1138,mri-based
1139,tobacco
1140,confounding
1141,inhibition
1142,pulse sequence
1143,nursing-sensitive
1144,enrollment
1145,tac
1146,waist
1147,multivariable-adjusted
1148,monomeric
1149,no
1150,dxa
1151,angiography
1152,events
1153,ventricular-arterial
1154,abnormal hr
1155,3.5-fold
1156,cardiac arrest
1157,analyses
1158,organizations
1159,eight-week-old
1160,expenditures
1161,regimens
1162,cabg
1163,interpretation
1164,metoprolol
1165,rule
1166,stimuli
1167,annulus velocity
1168,ventricular dilatation
1169,bnp
1170,motion
1171,choline
1172,two-vessel
1173,depresses
1174,in-hospital
1175,cycle
1176,untranslated
1177,ph
1178,embolectomy
1179,baseline electrocardiogram
1180,hscrp
1181,sdqt
1182,annuloplasty
1183,randomized
1184,dna
1185,brief
1186,rr
1187,nutritional
1188,non-fatal stroke
1189,interplay
1190,income
1191,antiplatelet
1192,indeterminable
1193,anaerobic
1194,defibrillator-crt
1195,imbalance
1196,metabolic
1197,comanagement
1198,congestion
1199,quality-adjusted survival
1200,e'septal
1201,reserve
1202,community-based
1203,kidney
1204,proteolysis
1205,post-myocardial
1206,uptitration
1207,case-fatality
1208,electrolytes
1209,nonfatal
1210,modestly
1211,idiopathic
1212,financial
1213,supports
1214,germline
1215,cardiology-cardiovascular
1216,induced
1217,cancers
1218,excised
1219,adenine
1220,intracellular
1221,co
1222,unloads
1223,slows
1224,substudy
1225,perturbations
1226,balance
1227,contracting
1228,multicenter
1229,actrn12610001087044
1230,lc-ms
1231,aggravate
1232,reverse
1233,classification
1234,matched
1235,cava
1236,c-statistics
1237,ameliorates
1238,randomized trials
1239,pacing-induced
1240,h-dko
1241,postsystolic
1242,major
1243,population
1244,cystatin
1245,stored
1246,circulatory derangement
1247,complexities
1248,uti
1249,nontrastuzumab
1250,sst2
1251,myeloma
1252,mediate
1253,examination
1254,hypothesis-generating
1255,non-lbbb
1256,impairment
1257,ecg
1258,aging
1259,congenital
1260,c-index
1261,radioenzymatic
1262,single
1263,attrition
1264,breath
1265,testing
1266,reversibility
1267,relative risk
1268,nanomolar
1269,hydrolysis
1270,tube
1271,grain
1272,pro-brain-type
1273,c-kit
1274,l-type voltage-gated
1275,beats
1276,statistic
1277,transcription factor
1278,hf-action
1279,inhibitors
1280,cardiography
1281,rwt
1282,physical performance
1283,spironolactone
1284,post-pd
1285,hypertrophic
1286,10-cell
1287,immunoassays
1288,histological
1289,b-type
1290,hyperkalemia
1291,intensive care
1292,icc
1293,costs
1294,implantations
1295,lv
1296,morphology
1297,hct
1298,mr-proanp
1299,astronaut
1300,intermacs
1301,direct
1302,aortic pressure curve
1303,atrioventricular delay
1304,length of stay
1305,tests
1306,well-being
1307,conflicting
1308,nt-probnp
1309,types of heart failure
1310,chm
1311,risk of heart failure
1312,consumption rate
1313,s'lateral
1314,mrnas
1315,race
1316,non-survivors
1317,high-volume
1318,deactivation
1319,extraction
1320,electronic
1321,quality-of-life
1322,gly16
1323,migration
1324,α-subunit
1325,liver
1326,antirheumatic
1327,course
1328,acute myocardial infarction
1329,e-wave
1330,inroads
1331,conduction
1332,public health
1333,deficits
1334,mixed-methods
1335,off-pump
1336,neurological
1337,end-diastolic pressure
1338,guidelines
1339,resistance
1340,intention-to-treat
1341,transfer
1342,anthracycline-containing
1343,cost-minimization
1344,ischemic
1345,smoked
1346,drugs
1347,pathway
1348,ventricularly
1349,reliability
1350,endoplasmic
1351,up-regulated
1352,fractions
1353,leg
1354,analyzed
1355,cultured
1356,median rate ratio
1357,point of care
1358,exposed
1359,difference-in-differences
1360,randomization
1361,medicare
1362,internal diameter
1363,cogeneration
1364,coated
1365,lung
1366,score-matched
1367,passive
1368,demographics
1369,source
1370,explants
1371,hand
1372,double
1373,beneficial effect
1374,wistar-kyoto
1375,cost-effectiveness
1376,low-strength
1377,chf-inv
1378,myxoma
1379,sham-innervated
1380,trigger
1381,non-linear
1382,qol
1383,reports
1384,furosemide
1385,devices
1386,high-sensitivity
1387,admissions
1388,function
1389,late-onset
1390,myoctyes
1391,converts
1392,fixed ring
1393,method
1394,influences
1395,esrd
1396,out-patient
1397,training-induced
1398,activate
1399,pathology
1400,constriction
1401,guidelines-heart
1402,sham-operated
1403,prodrug
1404,obstructed
1405,evolving
1406,pre-crt
1407,yields
1408,strip
1409,interactions
1410,moderate-quality
1411,shunt
1412,high-quality
1413,cell
1414,strain
1415,enos-thr
1416,practice
1417,trends
1418,likelihood
1419,instability
1420,small-molecule
1421,oxidase
1422,case
1423,mass spectrometric
1424,hdl-mediated
1425,tolerance
1426,irs2
1427,patient-years
1428,radiological
1429,rate
1430,rv
1431,reduction
1432,main effect
1433,nuclear
1434,review
1435,lipolysis
1436,mo
1437,relative reduction
1438,quality-of-life scores
1439,self-care
1440,ecmo
1441,breath-holding
1442,renin
1443,pka
1444,mir-25
1445,inflow velocity
1446,radial artery
1447,methodology
1448,atherosclerotic
1449,delivery
1450,electric
1451,enrolled
1452,congestion-like
1453,drs-stratified
1454,population-specific
1455,principal
1456,receptor
1457,subcellular
1458,clinical trials
1459,risks of hospitalization
1460,influence
1461,affects
1462,coefficient
1463,arthritis
1464,gene
1465,shift
1466,monocytes
1467,claims
1468,physiologic
1469,exercise-induced
1470,naviaux
1471,mechanistically
1472,activating
1473,cardiopulmonary
1474,median
1475,p70s6k-ser
1476,ip
1477,seven
1478,validation
1479,reassessed
1480,management
1481,antiadrenergic
1482,transgenic
1483,exclusion
1484,pump-exchange
1485,resynthesis
1486,remarkable
1487,signalling
1488,scn5a
1489,closure
1490,dcm
1491,early-activated
1492,s1pr1
1493,warranted
1494,proteomics
1495,micrornas
1496,prevention
1497,measurements
1498,fee-for-service
1499,t1-mapping
1500,pre-hct
1501,burden of heart failure
1502,bcl2
1503,fibrosis
1504,sustainability
1505,tapse-to-pasp ratio
1506,joint
1507,trans
1508,wk of treatment
1509,group
1510,public
1511,linear
1512,currents
1513,hospitals
1514,challenges
1515,society
1516,t cells
1517,hf
1518,impaired
1519,purpose
1520,hhd
1521,angioplasty
1522,acute kidney injury
1523,taxonomy
1524,pump
1525,new-onset
1526,evolution
1527,norepinephrine
1528,cox models
1529,bundle-branch
1530,anemic
1531,ethnic
1532,secretion
1533,rehabilitation
1534,aetiologies
1535,regulation
1536,icu
1537,norepinephrine-induced
1538,framework
1539,risk factor
1540,contractility
1541,gross
1542,right ventricular
1543,end-diastolic volume
1544,vitro
1545,covariates
1546,constructed
1547,findings
1548,receptors
1549,inhibitor
1550,core
1551,myocyte-specific
1552,surviving
1553,industrial
1554,regression
1555,contextual
1556,ventricular action potential
1557,adjunctive
1558,venoarterial
1559,precapillary
1560,commissioning
1561,structure
1562,cgmp
1563,transient
1564,outline
1565,pharmacological
1566,anthracycline
1567,beta-adrenergic
1568,comparisons
1569,social
1570,implanted
1571,natriuretic
1572,percutaneous
1573,tachycardic
1574,bromodomain
1575,atherosclerosis
1576,natriuretic peptides
1577,molecular
1578,six
1579,adenylyl
1580,wedge pressure
1581,downregulated
1582,icd-hf
1583,multivariate
1584,black race
1585,3-vessel
1586,ion
1587,erc
1588,self-identified
1589,mutant
1590,sham-dnx
1591,common
1592,principles
1593,communication
1594,myofibrillar
1595,nonterminal epitopes
1596,thirty-seven
1597,innovation
1598,exchanges
1599,health-care
1600,techniques
1601,fractional
1602,referrals
1603,hf-induced
1604,tactics
1605,patent
1606,placebo-treated
1607,preoperative
1608,database
1609,trend
1610,bivp
1611,high-density
1612,arrhythmia
1613,crt
1614,stand-alone
1615,diabetes
1616,meta-analyzed
1617,workload
1618,intubations
1619,branch
1620,risk of death
1621,inducing
1622,interquartile range
1623,radial
1624,hdl-bound
1625,early-outgrowth
1626,esc
1627,arrhythmias
1628,hf-related
1629,pressure
1630,valvular
1631,presentations
1632,cv
1633,design
1634,measure
1635,bisoprolol
1636,rrna
1637,renin-angiotensin-aldosteron
1638,implantation
1639,nuclear factor
1640,encoding
1641,midpapillary
1642,incidence
1643,precipitating factor
1644,nontreatment
1645,nucleotides
1646,hm
1647,vasopressin
1648,underperfusion
1649,injections
1650,anti-oxidant defence
1651,prediction
1652,fever
1653,leaflet
1654,anthracycline-induced
1655,second-generation
1656,post-hct
1657,seer-medicare
1658,6mwt
1659,interaction
1660,bhlh
1661,expenditure
1662,channels
1663,glycolysis
1664,inappropriate
1665,matrix
1666,classified
1667,thrombosis
1668,amyloidotic
1669,carvedilol
1670,action potentials
1671,sickle
1672,strokes
1673,n-terminal
1674,perioperative
1675,afterload
1676,acf
1677,consideration
1678,multivariate-adjusted
1679,α-myosin
1680,hypophosphorylation
1681,culprit
1682,sepsis
1683,alternative
1684,ctnt
1685,microstructure
1686,turnaround
1687,demographic
1688,bridge
1689,operation
1690,barriers to exercise
1691,donors
1692,human-to-machine
1693,uncontrolled hypertension
1694,low-frequency
1695,β1-adrenergic
1696,iron-deficient
1697,attenuation
1698,permeability
1699,right-sided
1700,independently
1701,yielded
1702,allopurinol
1703,atropine
1704,tachycardia-induced
1705,practice-level variation
1706,index admission
1707,resource
1708,organ
1709,subproteomes
1710,depression
1711,storm
1712,report
1713,angiotensin receptor
1714,rankings
1715,non-invasively
1716,intima-media
1717,appropriately
1718,glucose
1719,ai
1720,single-centre
1721,disciplines
1722,rationale
1723,pro-b-type
1724,double-knockout
1725,human-to-human
1726,remodelling
1727,responses
1728,differences
1729,new-user
1730,pathophysiology
1731,iron deficiency
1732,nfat
1733,rats
1734,denervation
1735,explant-derived
1736,muscles
1737,cr
1738,rcts
1739,susceptibility
1740,c-terminally
1741,propensity
1742,hf-ref
1743,expertise
1744,biological
1745,ci
1746,composite
1747,overload
1748,nonadherence
1749,aas
1750,polymorphism
1751,anthracycline-treated
1752,restriction
1753,beta-blocker
1754,diameter
1755,hazards
1756,cardioprotective
1757,anthracyclines
1758,cytoskeleton
1759,cfa
1760,processed
1761,prostate
1762,therapy
1763,technical
1764,isoforms
1765,carcinoma
1766,beat
1767,unfamiliar
1768,distribution
1769,endothelial
1770,hypotension
1771,characteristics
1772,thirds
1773,paf-cpt
1774,environment
1775,hemoglobin
1776,acute
1777,ankle-brachial index
1778,fat
1779,families
1780,transition
1781,adiponectin
1782,cornerstone
1783,identification
1784,baseline
1785,processes
1786,unanchors
1787,ischemic-hypertensive
1788,unloading
1789,derivation
1790,peptide
1791,regulatory
1792,nordic
1793,science
1794,infarction-related
1795,participants
1796,admission
1797,progenitor
1798,oversewing
1799,kcl-ki
1800,serum
1801,arrhythmia-related
1802,grading
1803,cardiogenic
1804,mechanically
1805,side effects
1806,cox
1807,infusion
1808,cases
1809,cardiomyopathy
1810,myofibre
1811,activation
1812,inotropic effect
1813,2+)-pump
1814,relationship
1815,vegfr2
1816,accounted
1817,link
1818,frailty
1819,multiparametric
1820,milliseconds
1821,reductions
1822,practice-level
1823,weight
1824,remodeling
1825,performers
1826,context
1827,iron
1828,ethically
1829,steady
1830,mediating
1831,parasympathetic
1832,strips
1833,long-term
1834,transplantations
1835,net
1836,ldl-cholesterol
1837,expression
1838,catabolic
1839,resynchronization
1840,conclusions
1841,postoperatively
1842,chromatin-associated
1843,ejection fraction
1844,spectrometry
1845,planning
1846,hypokalemia
1847,array
1848,interest
1849,absorption
1850,bromodomain-containing
1851,paradigm-hf
1852,capacity
1853,2-vessel
1854,policy
1855,network
1856,sequence
1857,cpr
1858,venous
1859,confidence
1860,isoenzymes
1861,sources
1862,consumption
1863,infrastructure
1864,pro-brain
1865,self-management
1866,drive
1867,rs
1868,end-diastolic
1869,echocardiographic
1870,fes
1871,mix
1872,hg
1873,electrocardiographic
1874,bypass
1875,tissue
1876,limits of agreement
1877,role
1878,secondary
1879,decompensation
1880,brd4
1881,rhythm-control
1882,severe
1883,aucs
1884,effects
1885,pharmaceuticals
1886,socioeconomic
1887,white
1888,free-breathing
1889,isoprenaline
1890,hfref
1891,individuals
1892,correction
1893,voltage-gated
1894,drs
1895,refuse
1896,fm
1897,channelopathies
1898,qtv
1899,limitation
1900,differential effect
1901,vco2
1902,unfit
1903,restoring
1904,matched-pairs
1905,eplerenone
1906,splicing
1907,endothelin
1908,hydrolytic
1909,cardioverter-defibrillator
1910,mechanics
1911,cardiac
1912,decrement
1913,treated
1914,cytotoxic
1915,gas
1916,primary
1917,density
1918,component
1919,progenitors
1920,blockade
1921,immunohistochemistry
1922,intervention
1923,annulus velocities
1924,rate-control
1925,results
1926,circumflex
1927,computational
1928,mr
1929,b-treated
1930,end-stage
1931,z-score
1932,matched cohort
1933,regurgitation
1934,ivabradine
1935,deficit
1936,fibrillation
1937,length-force
1938,potassium
1939,artery
1940,humanized
1941,methotrexate
1942,nbdmards
1943,pro-adrenomedullin
1944,long-acting
1945,genotyped
1946,n -
1947,mitral
1948,covariate
1949,effectiveness
1950,exhaustion
1951,noncardiovascular
1952,post-tac
1953,surgical
1954,stratification
1955,egfr
1956,pulse
1957,abrogated
1958,catabolism
1959,decile
1960,polymerase
1961,low-dose
1962,hart
1963,myofilament
1964,exerted
1965,post-translational
1966,system
1967,embryonic kidney
1968,financial incentives
1969,interquartile
1970,transplants
1971,pulse-wave velocity
1972,months of follow-up
1973,myofiber
1974,co-morbidity
1975,embedded
1976,wistar
1977,multisystem
1978,applicable
1979,waves
1980,high-fat
1981,mets
1982,overexpression
1983,clear organic lesion
1984,pna
1985,monitoring
1986,accountable
1987,model
1988,loading
1989,canine electromechanics
1990,flow velocity
1991,assay
1992,collateral
1993,collinearity
1994,databases
1995,if-channel
1996,stem cell-derived
1997,multisite
1998,conditions
1999,cross-sectional
2000,adaptive
2001,cardioverter-defibrillator deactivation
2002,ankle-brachial
2003,investigations
2004,magnetic resonance
2005,inverse
2006,institutions
2007,hospital
2008,unsuccessful
2009,signalosome
2010,beta
2011,pacemaker
2012,male
2013,nephropathy
2014,pneumonia
2015,intl
2016,infarcted
2017,integrated
2018,scale
2019,legal
2020,pilot
2021,misdiagnosis
2022,therapies
2023,viscoelastic
2024,rotor
2025,patients
2026,decoy
2027,large-scale
2028,stenosis
2029,ras-blocker
2030,anastomosis
2031,restorative
2032,gls
2033,treatment
2034,intermuscular
2035,transfusions
2036,air
2037,perfusion
2038,self-reported
2039,force
2040,psychosocial
2041,kccq
2042,level of agreement
2043,systemic
2044,all-cause mortality
2045,plasticity
2046,intake
2047,behavioural-change
2048,parallel-group
2049,response
2050,stroke
2051,atrial fibrillation
2052,electrical
2053,likelihood ratio
2054,cutoff
2055,exertion
2056,evidence
2057,etiologies
2058,deaths
2059,monitor
2060,hypoalbuminemia
2061,pairwise
2062,physical
2063,mt
2064,non-hf
2065,hgb
2066,warrants
2067,overstimulation
2068,impact
2069,tgf-β
2070,transverse aortic constriction
2071,dipeptidyl
2072,re-hospitalization
2073,healthcare
2074,repairs
2075,reprogramming
2076,rotation
2077,fraction
2078,haematopoietic
2079,pre-post comparisons
2080,carries
2081,looping
2082,patient
2083,publicly
2084,board
2085,resistive
2086,hemodynamically
2087,algorithms
2088,cardiotoxicity
2089,applications
2090,single-payer
2091,relevance
2092,time-dependent
2093,cfi
2094,lbbb
2095,conscious
2096,recruited
2097,angiotensin
2098,centers
2099,reversed
2100,replacement
2101,well-treated
2102,incubation
2103,inhospital
2104,study design
2105,endpoint
2106,epitopes
2107,hazard ratio
2108,activated
2109,readmissions
2110,insulin-signaling
2111,rose
2112,basis
2113,hall
2114,tgtetmena
2115,quality-of-life score
2116,cpet
2117,unfolded
2118,isoproterenol
2119,interleukin
2120,pathogenesis
2121,ring annuloplasty
